Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialLancet Diabetes Endocrinol 2021 Oct 04;[EPub Ahead of Print], HJL Heerspink, N Jongs, GM Chertow, AM Langkilde, JJV McMurray, R Correa-Rotter, P Rossing, CD Sjöström, BV Stefansson, RD Toto, DC Wheeler, T Greene
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.